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Continue, adjust, or stop antipsychotic
medication: developing and user testing
an encounter decision aid for people with
first-episode and long-term psychosis
Yaara Zisman-Ilani1* , David Shern2, Patricia Deegan3, Julie Kreyenbuhl4,5, Lisa Dixon6,10, Robert Drake7,
William Torrey8, Manish Mishra7, Ksenia Gorbenko9 and Glyn Elwyn7

Abstract
Background: People with psychosis struggle with decisions about their use of antipsychotics. They often want to
reduce the dose or stop, while facing uncertainty regarding the effects these decisions will have on their treatment
and recovery. They may also fear raising this issue with clinicians. The purpose of this study was to develop and test
a shared decision making (SDM) tool to support patients and clinicians in making decisions about antipsychotics.
Methods: A diverse editorial research team developed an Encounter Decision Aid (EDA) for patients and clinicians
to use as part of the psychiatric consultation. The EDA was tested using 24 semistructured interviews with
participants representing six stakeholder groups: patients with first-episode psychosis, patients with long-term
psychosis, family members, psychiatrists, mental health counselors, and administrators. We used inductive and
deductive coding of interview transcripts to identify points to revise within three domains: general impression and
purpose of the EDA; suggested changes to the content, wording, and appearance; and usability and potential
contribution to the psychiatric consultation.
Results: An EDA was developed in an iterative process that yielded evidence-based answers to five frequently
asked questions about antipsychotic medications. Patients with long-term psychosis and mental health counselors
suggested more changes and revisions than patients with first-episode psychosis and psychiatrists. Family members
suggested more revisions to the answers about potential risks of stopping or adjusting antipsychotics than other
respondents.
Conclusions: The EDA was perceived as potentially useful and feasible in psychiatric routine care, especially if
presented during the consultation.
Keywords: Shared decision making, Decision aid, Decision support tool, Option grid, Psychosis, Antipsychotic medication

Background
People with serious mental illness, such as schizophrenia, face decisions to continue, reduce or discontinue
antipsychotic medications daily. Many fail to formally
consult their psychiatrists as part of this decision
process. Few prescribers explicitly address this issue with
patients during the clinical encounter [1–3]. This
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situation illuminates two important points to consider in
clinical practice. First, it raises concerns about the effectiveness of antipsychotic medications as a primary approach for preventing relapse in psychosis [4]. Second,
people with serious mental illness make treatment decisions about their use of medications independently,
often without enough information gained in consultation
with psychiatrists and other mental health providers
about the likely risks and benefits [5–7].
Many studies have addressed the benefits and risks of
continuing antipsychotics [8–13] as well as the effects of
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nonadherence to antipsychotic medications and its antecedents, factors, and outcomes [3, 14, 15]. However, few
have focused on the decision-making process in psychiatric consultation or on how to present and discuss the
relevant options [16–21]. Existing studies suggest that the
use of a shared decision making (SDM) process in psychiatric medication consultations is preferred for making
mental health care decisions characterized by uncertainty
and when more than one reasonable option is available
[22]. Indeed, a recent review by the Australian National
Mental Health Consumer Carer Forum on the topic of
psychiatric medications concluded, among other things,
that a SDM approach encourages the empowered use of
psychiatric medications as part of the recovery process
and positions patients as active agents in their own recovery process [23].
SDM is a health communication model that helps patients and clinicians make treatment decisions jointly. It
gives both parties a framework and legitimacy for the
discussion [24], focuses on the patient–clinician interaction, and encourages open dialogue in which both parties have expertise, which should lead to the choice of a
consensus plan [25–27]. From an ethical perspective,
SDM embraces patients’ experiences, autonomy, and
empowerment, which are aligned with personal recovery
values and self-determination [28, 29].
One promising approach to operationalizing SDM in
the medical consultation is the use of an encounter decision aid (EDA) to help patients and clinicians discuss
relevant treatment options, support patients in exploring
what is clinically available, and incorporate patient preferences [30, 31]. EDAs are evidence-based tools used before, during, or after a medical encounter to supplement
the clinical consultation and to help patients make an
informed, deliberate choice among treatment options
[32, 33]. EDAs differ from health education materials because they make explicit a specific decision [34], and
simplify the information about the patient’s condition
and his or her options for treatment, screening, or diagnostic procedures. Previous research on the effects of
EDA on various patient populations generally supports
the potential positive effects of EDAs on patients’ medical decision-making: improving their knowledge regarding their treatment options and risk perceptions,
reducing their level of decisional conflict, and decreasing
the proportion of people who remain undecided [31].
However, this review included only two studies of EDAs
in mental health [16, 35], both showing the effects of the
EDA on uptake of psychoeducation [16] or completion
of psychotherapy [35], not on antipsychotic medications
adherence, which is strongly different from participation
in psychotherapy or psychoeducation. Therefore, although Stacey et al. [31] found strong evidence when
the patient choice is about whether to undergo surgery
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or treatment for heart failure or diabetes, their conclusions cannot be easily extended to patients with mental
disorders.
Indeed, previous reviews focusing specifically on SDM
in mental health have recommended using decision aids
when discussing treatment options [17, 36], but similar
biases and methodological limitations in the included articles, as with the findings by Stacey et al. [31], still exist.
A recent review of SDM interventions in mental health
by Zisman-Ilani et al. [37] included, in addition to randomized control trials (RCT), non-RCT studies and conceptual articles. The authors included 31 articles, of
which 12 have described decision aids (or EDAs); only
seven (of these 12 articles) were research articles and described an evaluation of a decision aid. Results were
mixed; in three studies that used a decision aid, without
supplemental elements before or after introducing it
(such as goal setting), there was at least one significant
outcome related to improved health behaviors (i.e. adherence, service utilization) [19, 38], mental health
symptoms [39], and SDM-related outcomes (i.e. involvement, knowledge, self-efficacy). One study [40] reported
no significant effect of the decision aid on patient outcomes. Four additional studies, that used a decision aid
with supplemental elements, were found to have at least
one positive significant effect on SDM-related outcomes
(i.e. involvement, knowledge, self-efficacy) [16, 18, 41],
and one study showed improved engagement in preferred treatment (psychotherapy, not medications) [35].
To help address the concerns from the limited studies
available from these reviews, our purpose in this study
was to develop a tool to help patients with psychosis
who have stabilized, their carers, and clinicians explicitly
address the daily dilemma of continuing, adjusting, or
discontinuing antipsychotics during the mental health
consultation. Specifically, our aims were: (1) to develop
an EDA for antipsychotic medications decision-making
that formally addresses the three options (continue, adjust, or stop); and, (2) to revise the tool based on a qualitative user-testing study with potential users that was
designed to evaluate the clarity, usability, and potential
barriers to and facilitators of future implementation of
the new EDA in psychiatric consultations.

Methods
The EDA was developed according to the recommendations of the International Patient Decision Aid Standards
(IPDAS) collaboration [42], the IPDAS instrument
(IPDASi) [43], and the previous experience of developing
50 Option Grids™ decision aids. We used a communitybased participatory research approach both in developing
the EDA and during the evaluation of the proposed EDA
by clinicians, carers and consumers [44]. The study had
two phases: (1) EDA development, and (2) user testing.
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Encounter decision aid development

We chose a specific format for the EDA, the Option Grid
decision aid for clinical encounters, that is short and that
can be implemented in routine care during medical encounters [45]. This format provides a simple one-page
table with rows containing frequently asked questions by
patients about their treatment options and the benefits,
risks, and implications of differing decisions. The columns
display the treatment options available for the health care
decision in question: here, continuing, adjusting, or discontinuing antipsychotic medications.
Creating an Option Grid decision aid of this nature requires a process that brings together the most current
scientific evidence and filters that data through a team
of health care experts. This team, which most often consists of service users, clinicians, and researchers, rigorously synthesizes evidence from systematic reviews and
the most reputable clinical guidelines in an editorial
process, hence, the name “editorial research team”.
Our multidisciplinary editorial research team included
people with lived experience of serious mental illness, psychiatrists, psychologists, a pharmacist, and decision scientists. The team developed the EDA between March 2015
and March 2016 within a larger project to create technical
assistance materials for use in first-episode-psychosis programs. As an editorial research team, we were not only involved in the development and user-testing of the tool but
also highly involved in the process of summarizing the evidence in an editorial process, especially when we had to
translate from primary or secondary research studies to
words and sentences that are accessible to patients and
other end-users of the tool. Our team met regularly to discuss development of the EDA and the user-testing strategy
and employed an iterative process [46] to create a final
version for the study.
The team focused on the often-neglected decision
node of what to do with antipsychotic medication management after a person has experienced symptom relief.
After opting to focus on medication decisions after initial stabilization, the team identified a series of frequently asked questions that can typify an informed
clinical interaction following stabilization from the first
episode. The questions that were ultimately selected are
portrayed in the rows of the EDA and address various
aspects of the three decisions that service users can
make following stabilization: Continuing on the medication regime that was used in their initial treatment;
Adjusting their antipsychotic medications and/or adding
medication for side effects; or Stopping the medications.
Following the identification of these questions, the research editorial team reviewed research literature to determine the most accurate responses to the questions.
Systematic reviews, treatment guidelines, meta-analyses,
and individual studies were included. Based on this
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process, draft answers to each of the frequently asked
questions were reviewed by the team for accuracy and
clarity. Each cell in the EDA matrix is linked to an evidence document (Additional file 1) that references the
research literature that supports the answers. When no
research base is available for a question, the opinion of
the editorial research team is cited.
User-testing study

Once an Option Grid decision aid is constructed, it is
put through a series of user tests and is refined until a
final version is agreed upon. This document is then used
during clinical encounters as a scaffolding of information
that prompts a deeper conversation about individuals’
specific desires for particular health care decisions.
Ultimately, an Option Grid is meant not to simply be a
stand-alone summary but a tool used to promote collaboration and deliberation.
Our user-testing included individual semistructured interviews with people from six stakeholder groups: persons
with first and long-term psychosis, family members of patients, psychiatrists, mental health counselors, and administrative staff at mental health clinics. Our team (YZI, DS,
MM, GE) developed an interview guide with three broad
sections: (1) general impression of the EDA and its purpose; (2) content, wording, accuracy, and visual appearance; and (3) perspectives on usability and implementation
in psychiatric settings (Table 1). We adapted the interview
guide to fit the six groups of interviewees.
Recruitment and procedures

Our team advertised the study and recruited potential
interviewees with the help of colleagues at two community mental health clinics in rural New Hampshire
(patients with long-term illness, psychiatrists, mental
health counselors, and administrators), a mental health
clinic for young adults with first-episode psychosis in the
New York City area affiliated with Mental Health
America (patients with first-episode psychosis), and a
support group for family members run by the National
Alliance on Mental Illness (family members of people
with a history of psychosis). We chose these sites based
on the relationships between some members of the editorial research team and these settings; some members
of the team helped open doors and access the specific
clinics and sites. However, these members had no direct
interaction with the study participants. In addition, the
lead author (YZI) conducted all interviews and had no
prior relationships with the clinics or the participants.
Using non-probability purposive sampling, we recruited
a convenience sample of interviewees based on population
characteristics and on the study’s objective to achieve a
final sample of diverse participant groups [47–49]. Specifically, we used expert sampling because our research
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Table 1 The semistructured interview guide for patients
General impression and purpose:
• Can you describe in your own words the purpose of the grid?
• What is your overall impression of the grid?
• In your opinion, who is the grid intended for?
• How helpful do you think such a tool would be for you for
decisions about the use of antipsychotic medication?
Content, wording, and appearance:

Page 4 of 11

collected would be confidential and used for research
purposes only. Interviewees were offered a $20 honorarium for their participation after the face-to-face interviews or $10 for telephone interviews (via mail). Each
interview lasted about 30 min. The Committee for the
Protection of Human Subjects at Dartmouth College approved the study.
Analysis

• Do you think there is room for such a tool in psychiatric care?

We used an iterative coding and analysis process with
constant comparison [50, 51]. Two authors (YZI, KG)
coded the interviews to ensure intercoder reliability and
conferred weekly [52]. Coders resolved discrepancies
through discussion. For example, codes were combined or
split after conferring with the other coder. After we
reached agreement on the themes, YZI wrote an evolving
qualitative memo, which was reviewed by KG biweekly.
Other authors (GE and DS) commented on ongoing drafts
of the results in both content and presentation. These versions of the tables and figures were presented to the entire
editorial research team to gather their feedback.

• Would you prefer a static version (paper and pencil) or an
interactive paper (for example on a tablet or mobile device)?

Results

• Is there anything you’d add, delete, or change about the opening
instructions of the DA?
• Is there anything you’d add, delete, or change about the
information in the row ‘What does this involve?’ †
• Are there other questions that you feel would be important to
include?
Usability and potential contribution to the psychiatric consultation:
• In your opinion, how would this tool best be incorporated into
aclinic’s workflow? (prompts: Before the visit at home? Before visit by
clinic staff? During visit? After visit?)

• Would you like the clinician to use this tool as part of your
meeting/consultation? (Why?)
• How do you think patients will respond to such a tool?

The encounter decision aid for antipsychotic medications

An EDA targeting three options (continue, adjust, or
stop medication) was developed (Additional file 2).

• How do you think clinicians will respond to such a tool?
†Four more questions like this were asked for each of the additional
rows in the decision aid.

requires first-hand experts in relation to antipsychotics
(prescribing, consulting, using, and caring for users) to
capture knowledge rooted in a particular form of expertise. It is common to use this purposive sampling technique in the early stages of a research process, when the
researchers are seeking to become better informed about
the topic at hand before embarking on a study. Eligibility
criteria varied by group category. Patients (first-episode
psychosis and long-term illness) had experienced at least
one episode of psychosis for which they took antipsychotic
medications, were age 18 years or older, and had a chart
diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or psychosis
not otherwise specified. Interviewees were excluded if they
could not speak, write, or read English or could not participate in an interview because their symptoms of psychosis were not stabilized by the time of the interview.
Patient interviews were conducted face-to-face. Interviews
with family members, clinicians, and administrative staff
were conducted face-to-face or by telephone.
We obtained verbal consent from all respondents at
the time of the interviews and written consent for faceto-face interviews. All interviewees were assured that
participation was voluntary and that all information

User testing of the encounter decision aid

We recruited 28 potential participants but excluded
four: one could not read, another was psychotic at the
beginning of the interview and could not participate in
the interview, and two were under the age of 18. The
final sample included 24 interviewees: five patients with
first-episode psychosis, six persons with long-term illness, five family members of persons with psychosis (not
related to the interviewed patients), six clinicians (three
psychiatrists and three mental health counselors), and
two health care administrators. All patients in the study
had an initial episode of psychosis or a long-term illness
but had stabilized. The sample size was sufficient to ensure diversity of perspectives for the purpose of our
study [53] and matched the development process of 50
existing EDAs at Dartmouth College. Our interviewees
represent diverse ages and genders. Their ages ranged
from 19 to 70 years, with family members 10 years older
on average than other interviewees. About half the interviewees were women (n = 14, 58.3%). All patients had
used or were currently using antipsychotic medication.
Domain 1: general impression and purpose of the decision aid

First impression: purpose and target audience All
participants clearly identified the EDA’s purpose as a tool
to help in decision-making regarding antipsychotic
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medications. They also almost uniformly reported that
the EDA was intended for people with a history of
psychosis. When prodded by the interviewer about the
EDA’s utility to clinicians, most interviewees added that
it might help clinicians. For example, one patient with a
first-episode psychosis suggested that the EDA might
help clinicians accustomed to making treatment decisions with little input from their patients become more
aware of patients’ perspective and desires: “I think it
could help [clinicians] too because they’re kind of old
school [.. . and. ..] [t]hey’re more on the side of you either taking it or switching medication.” Only one psychiatrist thought the EDA was primarily for clinicians.
A patient with a long-term illness noted that the EDA
might be more helpful to newly diagnosed people. By
contrast, a clinician commented that the EDA might be
most useful to people who have “reached a level of either
stability or. .. they feel they’re doing very, very well” and
begin to question their medication’s utility. A psychiatrist noted that uses of the EDA could extend to any
psychiatric encounters because “most people do stop
their antipsychotic medication or skip doses. .. [E]ven
when you start, it’s unrealistic to think that someone is
always taking their medication.”

First impression: utility A few patients told us that the
EDA would be useful to them. One patient said, “I
would really like to be able to use [the EDA], because it
would help me focus on what I need to pay attention to
in case something either went good or not so good when
we try changing my medication.” Psychiatrists and counselors commented that the EDA may enhance discussions about risks and benefits of antipsychotic
medications. They cautioned that focusing on side effects of antipsychotics may push their patients to consider stopping their use: “I’d feel great if [patients]
actually thought it out, instead of just deciding [to stop
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medications]. .. without thinking about, okay, well then
what might happen?”
First impressions: family concerns Of all stakeholders,
family members were the most guarded in their first reactions to the EDA. Some found unthinkable the idea of
discussing the option of stopping medication. One family member thought the EDA might help someone with
a high level of reading comprehension who can make rational decisions: “I think it’s intended for somebody who
can read and make judgments and understand it. .. Their
decision-making may not be at a level where they can
make a competent decision.” Another family member
was more ambivalent about the idea of involving patients in treatment decision-making: “I wonder how
someone who has severe mental illness and is controlling it through medication and also through counseling
would be able to judge this on their own without the
help of the professionals [.. .] how do you even bring. ..
up [stopping/adjusting medications] as a topic? Because
in some families, that’s like lighting a. .. powder keg.
And other families, I think it’s a great relief that somebody does finally bring it up.”
Domain 2: suggested changes to the content, wording, and
appearance of the decision aid

Most interviewees liked the EDA’s content, wording, and
appearance. Figure 1 summarizes the suggested revisions to
the EDA’s content, by question and by stakeholder group.
A total of 66 revisions were offered (we did not count
agreement with the text). Questions 3 and 4 (see below)
elicited the highest rates of dissatisfaction with the content.
Patients with long-term illness and mental health counselors suggested the most revisions to the EDA’s content.
†Suggested changes/dissatisfaction with the content.
Administrators’ responses are missing, as they were not
asked about the specific content of the EDA.

Fig. 1 Number of quotations† regarding the appearance and content of the EDA

Zisman-Ilani et al. BMC Psychiatry (2018) 18:142
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Suggested revisions to the title and instructions
Table 2 describes the user-testing version of the EDA,
dated March 2016, and the final version, dated July 2016.
Interviewees suggested using a simple, short, descriptive
title to reach a wide audience. One psychiatrist noted that
the term psychosis may be confusing to some patients,
particularly if they think of themselves as taking the medication “for an episode of confusion or an episode of extreme agitation and disorientation.” One family member
suggested that the EDA should frame the consultation as
a decision-making meeting from the beginning, to facilitate the process. This interviewee suggested using relevant
buzzwords in the instructions to reflect that the EDA is
intended to facilitate engagement in the treatment process
and to provide support in medication decision making.
The final wording of the instructions is as follow: “Use this
decision aid to help you, your caregiver, and your doctor
(prescriber) decide how to best manage your medication.
This decision aid is most appropriate for people who take
medication for psychosis and for those who have had
psychosis for the first time.”

valuable because these individuals can provide feedback
about the patient’s mental health. Patients mentioned
additional strategies for illness management such as participation in support groups and use of mobile apps.

Suggested changes to question 1: what does this involve?
Based on comments by several patients with long-term
illness, we changed the information in each of the cells
to be less deterministic (Table 2). We also wanted to
emphasize that stopping antipsychotics requires a gradual process.

I think [patients] would respond well [to the EDA]
depending on where they’re...in their disease. If it’s not
immediate crisis and they’re able to contemplate these
sort of things, then I think it would be very helpful for
them. (Family member)

Suggested changes to question 2: what are the benefits?
Participants identified an imbalance between the three
options and a bias toward stopping antipsychotic medications. One patient with a first-episode psychosis commented: “I think you should have more of the benefits
[of the medications] because it really does help [.. .] You
can just tell right away.”
Suggested changes to question 3: what are the risks?
As with Question 2, one patient mentioned that there
should be more balance between each option. A patient
with a long-term illness noted that sexual problems are a
major side effect that should be specifically mentioned.
Interestingly, a patient with a first-episode psychosis
shared with us that the need for frequent check-ups with
the community psychiatrist when adjusting or stopping antipsychotics is an important consideration for this decision.
She felt that young people might prefer to adhere to their
suggested dose in order to avoid frequent contact with the
psychiatrist, whereas patients with long-term psychosis
may be more likely to reduce and taper their medications.
Suggested changes to question 4: how can i reduce
the risks? Patients mentioned that having a trusting
relationship with people other than their clinician can be

Suggested changes to question 5: how might this
affect my usual activity? Interviewees suggested ending
the EDA with a positive take-home message, using the
active voice, to instill/foster hope. A patient with a longterm illness explained that some symptoms are tolerable
and that eliminating them is not always the ultimate goal.
Domain 3: Usability and potential contribution to the
psychiatric consultation

Interviewees felt that the EDA can be useful and feasible
in routine care. An administrator said, “[The EDA] gives
them something to follow along with as [the patient,
family member, or clinician is] talking.” This view was
supported by several patients. However, some interviewees felt that the usability would depend on the
patient’s stage of illness:

Some interviewees felt that the EDA may facilitate
better involvement in mental healthcare:
It gives you a choice [...] you’re able to look at what
are the benefits, side effects and stuff, how continuing
medication or stopping the medication or adjusting
the medication, it gives you a choice to look at all
three of them. (Patient with long-term psychosis)
Family members mentioned that the EDA may increase the patient’s awareness of their options including
stopping medication, and that this option/issue is not
usually discussed: “I think a lot of people wouldn’t have
even considered these options [unless their provider
shows them the EDA].”

Discussion
The newly developed EDA was positively evaluated by
the different stakeholders who participated in usertesting. The EDA was perceived as usable, contextappropriate, and potentially feasible in psychiatric
consultations. Some respondents, particularly patients
and family members, were concerned that the early version of the EDA strongly advocated against antipsychotic
medications, which led to revisions to the final version.
Interviewees encouraged us to present the information

Zisman-Ilani et al. BMC Psychiatry (2018) 18:142
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Table 2 Changes in the encounter decision aid based on participants’ feedback from the user testing to the final version
Continue
Title

Instructions

Q1

Q2

Q3

Q4

Q5

March 2016

Adjust

Stop

Use of antipsychotic medications after recovering from past episode of psychosis

July 2016

Antipsychotic medication: continue, adjust, or stop? for people who have stabilized

March 2016

Use this Option Grid™ decision aid to help you and your clinician consider how best to manage your
antipsychotic medications.

July 2016

Use this decision aid to help you, your caregiver, and your doctor (prescriber) decide how to best manage your
medication. This decision aid is most appropriate for people who take medication for psychosis and for those
who have had psychosis for the first time.

March 2016

Making no changes to the medications
you take.

Taking more or less medication, adding
or changing if needed. It is best to take
the fewest number of medicines at the
lowest dose. This often needs
adjustments and is best done
with help from your clinician.

Gradually stopping your medications.
This is best done with help from your
clinician and may involve learning
other strategies to manage your
symptoms.

July 2016

Making no changes to your
medications. Please ask your doctor
about the effects of continuing to
use antipsychotic medications. It is
important to work closely with your
doctor.

Taking more or less medication, adding
or changing if needed. It is best to take
the fewest number of medications at
the lowest dose that works. Adjusting
medication is best done with help
from your doctor.

Slowly stopping your medications.
This is best done with help from
your doctor and may involve
learning other ways to manage
your symptoms.

March 2016

You can expect things to stay the
same, both the good and the bad.

You can experience fewer medication
related side effects, such as sleepiness,
uncontrollable movements and weight
gain.

You can avoid medication side
effects such as sleepiness,
uncontrollable movements
and weight gain.

July 2016

You can expect things to stay the
same. Medications can help you focus
less on symptoms and more on the
things that are important to you, like
work or school.

You may have fewer medication
side effects, such as sleepiness,
uncontrollable movements and
weight gain.

No revisions

March 2016

You might be on too high dose or
too much medication. Common side
effects are sleepiness, uncontrollable
movements and weight gain.

Problems may come back on a lower
dose, and you may have more difficulty
working or concentrating. You may
need more check ups to be sure that
symptoms don’t come back.

Symptoms may get worse if
medications are stopped. Roughly 80
in every 100 people (80%) will suffer
symptoms again in one year after
stopping medications. These symptoms
may cause you to go back into the
hospital.

July 2016

Common side effects are sleepiness,
uncontrollable movements, weight
gain, and other effects such as sexual
problems. You might not be on the
dose or combination of medications
that’s best for you.

Symptoms may come back on a lower
dose, and you may find it hard to work
or concentrate. You may need more
check-ups with your doctor to make
sure that symptoms don’t come back.

Your symptoms may get worse if you
stop taking medication. Roughly 80 in
every 100 people (80%) will have
symptoms again in the year after
stopping medications. These symptoms
may cause you to go back to a
hospital or psychiatric community
clinic.

March 2016

Try to find ways to limit side effects.
You might want to eat health food,
join patient groups and stay physically
active. Avoid using alcohol or street
drugs because they can make it hard
to understand if your medications are
working

Keep track of how you feel, using a
journal so that you know if your
medications are helping or not, and
share it with your clinician. Maybe ask
someone to give you feedback about
how you are doing. Avoid using alcohol
or street drugs because they can make
it hard to understand if your
medications are working.

Make sure that you have frequent
contact with your clinician. Follow the
schedule as you reduce the the
medicine dose. Don’t downplay your
symptoms if they come back. Avoid
using alcohol or drugs because they
can make it hard to understand if your
medications are working.

July 2016

You can try to find ways to limit
side effects, such as by eating
healthy food, joining patient
groups and staying physically
active. Avoid alcohol and street
drugs.

Keep track of how you feel and talk
with your doctor. You can try support
groups, mobile apps, or writing in a
journal so that you know if your
medications are helping or not. You
can ask someone to give you feedback
about how you are doing.
Avoid alcohol and street drugs.

Talk regularly with your doctor, a
mental health counselor, family
members or a friend. Follow the
schedule as you lower the medication
dose. Don’tdownplay your symptoms if
they come back.
Avoid alcohol and street drugs.

March 2016

If the medications are being
helpful, then you would get back
to your usual activities.

Taking the lowest effective dose will
cause fewer side effects. Being more alert
and less bothered by side effects may
help you get back to your normal activities.

It is likely that your symptoms will
come back and make it more difficult
to do your normal activities.
Stay in close contact with your
clinician.
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Table 2 Changes in the encounter decision aid based on participants’ feedback from the user testing to the final version
(Continued)
July 2016

Continue

Adjust

Stop

No revisions

Taking the lowest dose that works will
cause fewer side effects. This may help
you get back to your usual activities.

Once your symptoms improve,
you will be able to go back to your
usual activities. However,
your symptoms will likely come back
at some point. Stay in touch with
your doctor.

neutrally. This recommendation is aligned with previous
work on the role of persuasive approaches in medical
decision-making and the need to determine whether
medical decisions are the result of a doctor–patient partnership or of persuasive tactics based. on power and
hierarchical relationships [54]. Persuasive theories are
one subset of health communication theories; they can
be applied at many levels including intrapersonal, interpersonal, organizational, and mass communication [55].
Accordingly, persuasion can play a critical role in doctor–patient communication, as it is often the intent of
a practitioner to shape, reinforce, or change a patient’s
behavior [56], especially when discussing medication
and treatment adherence [55], and even more in psychiatric settings, where patients are often questioned
about their ability and capability to make treatment
decisions [17, 57].
Our respondents raised the issue of patients’ ability to
make decisions. This is particularly relevant to patients
with schizophrenia spectrum disorders and serious mental
illness, who may lack awareness of their illness [58–60].
However, findings from the last decade about SDM in
mental health provide evidence that people with mental
conditions, including schizophrenia [16], can effectively
participate in SDM with their health provider [37] and will
make medication decisions independently without clinical
guidance [23]. Therefore, because people with long-term
illness provided most of the revisions to the EDA’s wording
and content, this may demonstrate their ability and capacity to engage in these ideas as well as anyone else, challenging perhaps the assumption that they lack capacity.
Family members were guarded in their initial reactions to
the EDA, perhaps fearing that discussion of stopping medication might suggest an alternative that would harm their
family member. Another explanation might be related to a
sense of family burden in caring for a loved one with a
mental illness [61–63], and a fear of a sudden increase in
this burden may explain family members’ concerns about
the EDA. Because family members play a major role in a
triadic decision-making in mental health care [64, 65], their
concerns are valid and should be addressed to facilitate and
support the discussion on medication management. The
present EDA and future SDM tools should include family
members as targeted end-users, along with patients and clinicians, to support implementation and increase buy-in.

Our study has several strengths: First, we presented a
heterogeneous overall sample representing unique access
to the different stakeholder groups that created an important diversity of participant groups in the final sample. Second, we have described the development of a
tool using a participatory approach that considered participants “active consultants” rather than “research subjects.” This research approach allows people with severe
mental illness / psychotic illness, who may be largely excluded from decisions about their treatment, to become
actively involved in the research and provide important
feedback. Therefore, not only may SDM and tools such
as decision aids help shift the power balance in medical
encounters to help address coercive treatment, but also
the participatory approach may help patients feel valued
for their input, which, in turn, may further empower
them. These strengths allowed us to explore and compare the different perceptions and perspectives of people
with lived experiences of antipsychotic medication management. Yet, several limitations should be noted: First,
the relatively small sample in each group may affect the
generalizability of the results. Second, the intention of
this article is not to venture into making suggestions
about clinical impact, as this was a small, qualitative
user-testing. Future field-testing research in various settings, such as clinics, hospitals, and community programs, is needed. In addition, future potential research
would require a further study with much larger samples
to test the effectiveness of the EDA and should include
clinical and more psychosocial impact measurements.

Conclusions
Our participants, people who are involved in antipsychotic medication management, found the EDA to be
valuable and acceptable. Our aim in this research and
article was not to provide answers or to solve the dilemma of whether to continue, adjust, or stop antipsychotic medications. We believe it is a very personal
decision that has no “one-size-fits-all” answer. Our aim
in this project was to give voice and room for such a
question/dilemma to be openly addressed as part of the
psychiatric encounter and to help patients and other
people involved in their care to “lay their cards on the
table” and to openly raise concerns and questions about
antipsychotics. As one of our interviewees shared with
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us: “I think a lot of people wouldn’t have even considered these options [unless their provider shows them the
EDA].” We hope that this EDA will help patients and
carers openly raise the dilemma, without fearing the response to and stigma associated with people with serious
mental illness who wish to stop or adjust their medications [4, 66]. We anticipate that giving this dilemma
room and space to be addressed as part of a psychiatric
consultation may have a personal-rehabilitative benefit
for the person with the illness as well as for others involved in his/her care. We hope that use of this EDA in
psychiatric consultations will contribute to making
personalized-better choices, ones that patients understand, agree to, and are more likely to follow, and that
use of the EDA will encourage an open discussion between patients and their care team, improving engagement in psychiatric care.
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